ExonHit to Buy RedPath Integrated Pathology

The acquisition of the Pittsburgh-based cancer testing company will bolster ExonHit’s molecular diagnostic position and its US presence.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories